Intravenous ghrelin administration to CHF patients for 3 weeks has been shown to increase LV ejection fraction (LVEF), LV mass, [40] maximal exercise tolerance, and maximal oxygen consumption, while decrease LV end-diastolic volume [98]. The gene discussed is GHRL; the disease is congestive heart failure.